EGFR and neoplasm: Thus, the sensitivity of EGFR‐TKIs in patients with non‐ADC harboring EGFR mutations may depend on the proportion of EGFR‐mutated ADC components in the whole tumor.8 However, this does not explain why some EGFR‐mutated non‐ADC patients respond completely to EGFR‐TIKs, as in our case.